PUBLISHER: DataM Intelligence | PRODUCT CODE: 1373379
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1373379
Advanced wound care products are used to treat acute and chronic wounds. Conventional wound care products have been replaced with advanced wound care products. The advanced wound care products show an efficient recovery.
Advanced wound care products such as collagen, biological dressings, biological skin equivalents, keratinocytes, platelet-derived growth factor, platelet-rich plasma, silver products, intermittent pneumatic compression therapy, negative pressure wound therapy, electromagnetic therapy, hyperbaric oxygen, topical oxygen, and ozone oxygen have been employed for the wound care.
The growing incidence of chronic ailments such as diabetes is driving the growth of the market. The number of Canadians living with chronic ulcers is increasing due to the prevalence of diabetes, and venous and arterial diseases. Diabetic patients exhibit a documented impairment in the healing of acute wounds. This may lead to severe wound infections.
For instance, according to the report Canadian Diabetes Association in 2022, there are more than 5.7 million Canadians living with diabetes (type 1 & type 2 diagnosed + type 2 undiagnosed), however, there are 11.7 million Canadians living with diabetes or prediabetes.
Additionally, according to the article published by the Canadian Journal of Diabetes in 2021, it is estimated that 4.6% of people with diabetes have an active DFU. Thus, an increase in the number of diabetes cases diabetic ulcers, and chronic wounds among people in the region, is expected to raise the market growth in the country.
The lack of federal monitoring or supporting authority for advanced wound care is limiting developments and access to patients in this sector, thus hindering market growth in the country. The lack of a federal wound care management program is another factor restricting the growth of the advanced wound care market in Canada.
Exudate is fluid that leaks out of blood vessels into nearby tissues. The fluid is made of cells, proteins, and solid materials. Exudate may ooze from cuts or from areas of infection or inflammation called pus. To manage the exudate a number of products have been released and introduced to the patients.
Increase in the number of woundcare product launches and the introduction of advanced products is expected to drive market growth. For instance, in April 2023, Kerecis launched the MariGen Shield which combines the company's fish-skin graft and a silicone contact layer to treat chronic and complex wounds. The latest product is fenestrated to enable proper drainage of wounds.
On October 11, 2022, Healthium Medtech launched a new wound dressing portfolio Theruptor Novo for the management of chronic wounds like diabetic foot ulcers and leg ulcers. Theruptor Novo is an anti-microbial and non-toxic wound dressing with technology patented in the US, India, EU, and Canada.
Delivering acute and chronic wound care with physical distancing measures has been a major challenge during COVID-19. The spread of infections has alerted patients who require wound care. The reduction in the usage of the products and supply chain interruptions due to the lockdown has influenced the market growth negatively.
The leading companies with a significant market share include: Exciton Technologies Inc., Medtronic Plc, Philips Healthcare, ConvaTec, Inc., Molnlycke Healthcare, Medline, Industries, Inc., Derma Sciences, Inc., Smith & Nephew Inc., Covalon Technologies Ltd., B. Braun Melsungen AG.
The Canada advanced wound care market report would provide approximately 69 tables, 68 figures, and 185 Pages.
LIST NOT EXHAUSTIVE